Gastrointestinal microbiome modulator improves glucose tolerance in overweight and obese subjects: A randomized controlled pilot trial.

Journal of diabetes and its complications. 2020;29(8):1272-6

Plain language summary

There is an increasing need for nutraceuticals that promote satiety and address the adverse health consequences obesity. Recent evidence suggests that the gut microbiome may play an important role in regulating metabolic pathways involved in obesity, particularly those involved in insulin resistance. This study used a gastrointestinal microbiome modulator (GIMM) containing inulin, oat beta-glucan, blueberry anthocyanins and blueberry polyphenols to examine its effects on metabolic parameters, faecal markers of gut microbiota and satiety. Thirty overweight or obese individuals were randomised to either consume the GIMM or placebo tablet for four weeks. Stool and blood samples were collected at the baseline and end of the trial, and satiety was assessed weekly. This study showed that GIMM consumption significantly improved blood glucose tolerance and increased satiety in overweight and obese participants. Further cellular studies are warranted to identify the specific pathways by which GIMM improves glucose control.


OBJECTIVE The objective of this study was to examine the effects of a gastrointestinal microbiome modulator (GIMM) containing inulin, β-glucan, blueberry anthocyanins, and blueberry polyphenols on metabolic parameters, fecal markers of gut microbiota, and satiety. DESIGN AND METHODS Thirty overweight or obese individuals aged 18 to 70years, were enrolled in a randomized controlled trial. Participants consumed the test product or placebo daily for four weeks. Stool samples were collected and blood was drawn at baseline and week four for assessments of gut microbiota, satiety hormones, glucose control, and lipid measures. Subjective satiety was assessed weekly. Linear models were used to compare differences from baseline to week four. RESULTS GIMM consumption improved blood glucose tolerance (p=0.008), and increased satiety (p=0.03). There were no statistically significant differences in insulin sensitivity, fecal markers of gut microbiota, plasma satiety hormones, or serum lipid concentrations between the groups. However, plasma satiety hormones and fecal short chain fatty acid concentrations increased in the test group compared to the placebo. CONCLUSIONS GIMM consumption for four weeks, increases satiety, and improves glucose tolerance possibly through insulin-independent pathways.

Lifestyle medicine

Fundamental Clinical Imbalances : Immune and inflammation
Patient Centred Factors : Mediators/Obesity
Environmental Inputs : Diet ; Nutrients
Personal Lifestyle Factors : Nutrition
Functional Laboratory Testing : Blood ; Stool
Bioactive Substances : Betaglucans

Methodological quality

Allocation concealment : Yes


Nutrition Evidence keywords : Gastrointestinalmicrobiomemodulator ; GIMM ; Inulin ; Flavonoids ; Blueberry